18 Members•4,119 Posts

Pharma & Biotech

Coiled Therapeutics targets cancer partnering deals after promising trial data

May 6, 2026

Ian Lyall

Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance

May 5, 2026

Angela Harmantas

ImmuPharma launches regulatory push for Kapiglucagon diabetes drug

May 5, 2026

Ian Lyall

BioVie advances long COVID trial, top-line data expected by summer

May 4, 2026

Steve Darling

Inside Biotech: EZZ taps viral ingredient trend with MeTime wellness launch

May 4, 2026

Lisa Uhlman

Arovella Therapeutics board changes after shareholder requisition notice

May 4, 2026

Jonathan Jackson

Candel Therapeutics to review Phase 3 prostate cancer data in May 15 call

May 4, 2026

Angela Harmantas

Orthocell's Remplir achieves 90% success rate in real-world patient data - ICYMI

May 2, 2026

Jonathan Jackson

Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT - Health and Biotech Week in Review

May 2, 2026

Stephen Gunnion

Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings

May 1, 2026

Emily Jarvie

Recce Pharmaceuticals advances US Army burn wound program and Indonesia Phase 3 trial in March quarter

May 1, 2026

Jonathan Jackson

Lumos Diagnostics raises $265,000 through share purchase plan as FebriDx rollout gathers pace

May 1, 2026

Lisa Uhlman

AstraZeneca falls as FDA advisers reject breast cancer drug use

May 1, 2026

Oliver Haill

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

May 1, 2026

Jamie Ashcroft

Shield Therapeutics drops as CFO exits and Medicaid concerns weigh

May 1, 2026

Oliver Haill

Imugene flags strong azer-cel response rates and ASCO milestone in March quarter update

Apr 30, 2026

Lisa Uhlman

Prescient Therapeutics advances PTX-100 trial and cell therapy platforms

Apr 30, 2026

Jonathan Jackson

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

Apr 30, 2026

Ian Lyall

Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts

Apr 30, 2026

Ian Lyall

Percheron Therapeutics raises $2.2 million as HMBD-002 phase II preparations advance

Apr 30, 2026

Jonathan Jackson

Powered by RoundtableAn AI/DeFi-powered Enterprise Media Operating System. Learn more at Roundtable.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy